Bupropion inhibits human α3β4 nicotinic acetylcholine receptors by interacting with luminal and non-luminal sites

Autores
Arias, Hugo Rubén; Feuerbach, D; Ortells, Marcelo Oscar
Año de publicación
2017
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
In this work, the interaction of (±)-bupropion [(±)-BP] and (±)-2-(N-tert-butylamino)-3’-iodo-4’- azidopropiophenone [(±)-SADU-3-72] with the human (h) α3β4 nicotinic acetylcholine receptor (AChR) is determined by functional and structural approaches. The Ca2+ influx results indicate that (±)-BP inhibits hα3β4 AChRs with ~2-fold lower potency than that for (±)-SADU-3-72, indicating that this photoreactive analog can be used to further characterize the (±)-BP binding sites. The competition binding results show that (±)-BP binds to the [3 H]imipramine sites at desensitized hα3β4 AChRs with ~4-fold higher affinity compared to the resting state. Molecular docking results indicate that both enantiomers of BP and SADU-3-72, in the protonated state, interact with luminal and non-luminal sites. BP interacts with a luminal site which overlaps that for imipramine, and with non-luminal sites located in the transmembrane domain (TMD) at interfacial (+α3/-β4) and α3 intrasubunit sites, and in the TMD-ECD (extracellular domain) junction at the +β4/-α3 and +β4/-β4 interfaces. Our results are consistent with a hα3β4 model where BP and SADU-3-72 bind to overlapping non-luminal sites as well as non-overlapping luminal sites, probably in physiological conditions. This work expands on previous studies supporting the notion that structurally different antidepressants produce their clinical effects by inhibiting distinct AChR subtypes.
Fil: Arias, Hugo Rubén. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad de Morón; Argentina
Fil: Feuerbach, D. Novartis Institutes for Biomedical Research; Suiza
Fil: Ortells, Marcelo Oscar. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad de Morón; Argentina
Materia
NICOTINIC RECEPTOR
BUPROPION
MOLECULAR MODELING
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/73221

id CONICETDig_d5d1e0d1c9f13fcad448a9685eaf6197
oai_identifier_str oai:ri.conicet.gov.ar:11336/73221
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Bupropion inhibits human α3β4 nicotinic acetylcholine receptors by interacting with luminal and non-luminal sitesArias, Hugo RubénFeuerbach, DOrtells, Marcelo OscarNICOTINIC RECEPTORBUPROPIONMOLECULAR MODELINGhttps://purl.org/becyt/ford/3.1https://purl.org/becyt/ford/3In this work, the interaction of (±)-bupropion [(±)-BP] and (±)-2-(N-tert-butylamino)-3’-iodo-4’- azidopropiophenone [(±)-SADU-3-72] with the human (h) α3β4 nicotinic acetylcholine receptor (AChR) is determined by functional and structural approaches. The Ca2+ influx results indicate that (±)-BP inhibits hα3β4 AChRs with ~2-fold lower potency than that for (±)-SADU-3-72, indicating that this photoreactive analog can be used to further characterize the (±)-BP binding sites. The competition binding results show that (±)-BP binds to the [3 H]imipramine sites at desensitized hα3β4 AChRs with ~4-fold higher affinity compared to the resting state. Molecular docking results indicate that both enantiomers of BP and SADU-3-72, in the protonated state, interact with luminal and non-luminal sites. BP interacts with a luminal site which overlaps that for imipramine, and with non-luminal sites located in the transmembrane domain (TMD) at interfacial (+α3/-β4) and α3 intrasubunit sites, and in the TMD-ECD (extracellular domain) junction at the +β4/-α3 and +β4/-β4 interfaces. Our results are consistent with a hα3β4 model where BP and SADU-3-72 bind to overlapping non-luminal sites as well as non-overlapping luminal sites, probably in physiological conditions. This work expands on previous studies supporting the notion that structurally different antidepressants produce their clinical effects by inhibiting distinct AChR subtypes.Fil: Arias, Hugo Rubén. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad de Morón; ArgentinaFil: Feuerbach, D. Novartis Institutes for Biomedical Research; SuizaFil: Ortells, Marcelo Oscar. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad de Morón; ArgentinaSmart Science & Technology LLC2017-12info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/73221Arias, Hugo Rubén; Feuerbach, D; Ortells, Marcelo Oscar; Bupropion inhibits human α3β4 nicotinic acetylcholine receptors by interacting with luminal and non-luminal sites; Smart Science & Technology LLC; Neurotransmitter; 5; 12-2017; 1-112375-2440CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/doi/10.14800/nt.1631info:eu-repo/semantics/altIdentifier/url/www.smartscitech.com/index.php/NT/article/view/1631info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-03T10:02:31Zoai:ri.conicet.gov.ar:11336/73221instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-03 10:02:32.153CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Bupropion inhibits human α3β4 nicotinic acetylcholine receptors by interacting with luminal and non-luminal sites
title Bupropion inhibits human α3β4 nicotinic acetylcholine receptors by interacting with luminal and non-luminal sites
spellingShingle Bupropion inhibits human α3β4 nicotinic acetylcholine receptors by interacting with luminal and non-luminal sites
Arias, Hugo Rubén
NICOTINIC RECEPTOR
BUPROPION
MOLECULAR MODELING
title_short Bupropion inhibits human α3β4 nicotinic acetylcholine receptors by interacting with luminal and non-luminal sites
title_full Bupropion inhibits human α3β4 nicotinic acetylcholine receptors by interacting with luminal and non-luminal sites
title_fullStr Bupropion inhibits human α3β4 nicotinic acetylcholine receptors by interacting with luminal and non-luminal sites
title_full_unstemmed Bupropion inhibits human α3β4 nicotinic acetylcholine receptors by interacting with luminal and non-luminal sites
title_sort Bupropion inhibits human α3β4 nicotinic acetylcholine receptors by interacting with luminal and non-luminal sites
dc.creator.none.fl_str_mv Arias, Hugo Rubén
Feuerbach, D
Ortells, Marcelo Oscar
author Arias, Hugo Rubén
author_facet Arias, Hugo Rubén
Feuerbach, D
Ortells, Marcelo Oscar
author_role author
author2 Feuerbach, D
Ortells, Marcelo Oscar
author2_role author
author
dc.subject.none.fl_str_mv NICOTINIC RECEPTOR
BUPROPION
MOLECULAR MODELING
topic NICOTINIC RECEPTOR
BUPROPION
MOLECULAR MODELING
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.1
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv In this work, the interaction of (±)-bupropion [(±)-BP] and (±)-2-(N-tert-butylamino)-3’-iodo-4’- azidopropiophenone [(±)-SADU-3-72] with the human (h) α3β4 nicotinic acetylcholine receptor (AChR) is determined by functional and structural approaches. The Ca2+ influx results indicate that (±)-BP inhibits hα3β4 AChRs with ~2-fold lower potency than that for (±)-SADU-3-72, indicating that this photoreactive analog can be used to further characterize the (±)-BP binding sites. The competition binding results show that (±)-BP binds to the [3 H]imipramine sites at desensitized hα3β4 AChRs with ~4-fold higher affinity compared to the resting state. Molecular docking results indicate that both enantiomers of BP and SADU-3-72, in the protonated state, interact with luminal and non-luminal sites. BP interacts with a luminal site which overlaps that for imipramine, and with non-luminal sites located in the transmembrane domain (TMD) at interfacial (+α3/-β4) and α3 intrasubunit sites, and in the TMD-ECD (extracellular domain) junction at the +β4/-α3 and +β4/-β4 interfaces. Our results are consistent with a hα3β4 model where BP and SADU-3-72 bind to overlapping non-luminal sites as well as non-overlapping luminal sites, probably in physiological conditions. This work expands on previous studies supporting the notion that structurally different antidepressants produce their clinical effects by inhibiting distinct AChR subtypes.
Fil: Arias, Hugo Rubén. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad de Morón; Argentina
Fil: Feuerbach, D. Novartis Institutes for Biomedical Research; Suiza
Fil: Ortells, Marcelo Oscar. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad de Morón; Argentina
description In this work, the interaction of (±)-bupropion [(±)-BP] and (±)-2-(N-tert-butylamino)-3’-iodo-4’- azidopropiophenone [(±)-SADU-3-72] with the human (h) α3β4 nicotinic acetylcholine receptor (AChR) is determined by functional and structural approaches. The Ca2+ influx results indicate that (±)-BP inhibits hα3β4 AChRs with ~2-fold lower potency than that for (±)-SADU-3-72, indicating that this photoreactive analog can be used to further characterize the (±)-BP binding sites. The competition binding results show that (±)-BP binds to the [3 H]imipramine sites at desensitized hα3β4 AChRs with ~4-fold higher affinity compared to the resting state. Molecular docking results indicate that both enantiomers of BP and SADU-3-72, in the protonated state, interact with luminal and non-luminal sites. BP interacts with a luminal site which overlaps that for imipramine, and with non-luminal sites located in the transmembrane domain (TMD) at interfacial (+α3/-β4) and α3 intrasubunit sites, and in the TMD-ECD (extracellular domain) junction at the +β4/-α3 and +β4/-β4 interfaces. Our results are consistent with a hα3β4 model where BP and SADU-3-72 bind to overlapping non-luminal sites as well as non-overlapping luminal sites, probably in physiological conditions. This work expands on previous studies supporting the notion that structurally different antidepressants produce their clinical effects by inhibiting distinct AChR subtypes.
publishDate 2017
dc.date.none.fl_str_mv 2017-12
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/73221
Arias, Hugo Rubén; Feuerbach, D; Ortells, Marcelo Oscar; Bupropion inhibits human α3β4 nicotinic acetylcholine receptors by interacting with luminal and non-luminal sites; Smart Science & Technology LLC; Neurotransmitter; 5; 12-2017; 1-11
2375-2440
CONICET Digital
CONICET
url http://hdl.handle.net/11336/73221
identifier_str_mv Arias, Hugo Rubén; Feuerbach, D; Ortells, Marcelo Oscar; Bupropion inhibits human α3β4 nicotinic acetylcholine receptors by interacting with luminal and non-luminal sites; Smart Science & Technology LLC; Neurotransmitter; 5; 12-2017; 1-11
2375-2440
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/doi/10.14800/nt.1631
info:eu-repo/semantics/altIdentifier/url/www.smartscitech.com/index.php/NT/article/view/1631
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Smart Science & Technology LLC
publisher.none.fl_str_mv Smart Science & Technology LLC
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1842269761152483328
score 13.13397